Sk Biopharmaceuticals Co Ltd (326030) - Total Assets
Based on the latest financial reports, Sk Biopharmaceuticals Co Ltd (326030) holds total assets worth ₩1.20 Trillion KRW (≈ $812.08 Million USD) as of December 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Check 326030 cash reinvestment to operating cash ratio to assess the company's total reinvestment commitment from operating cash flow.
Sk Biopharmaceuticals Co Ltd - Total Assets Trend (2016–2025)
This chart illustrates how Sk Biopharmaceuticals Co Ltd's total assets have evolved over time, based on quarterly financial data. Check Sk Biopharmaceuticals Co Ltd (326030) cash flow quality to evaluate the quality of earnings relative to operating cash generation.
Sk Biopharmaceuticals Co Ltd - Asset Composition Analysis
Current Asset Composition (December 2025)
Sk Biopharmaceuticals Co Ltd's total assets of ₩1.20 Trillion consist of 57.0% current assets and 43.0% non-current assets.
| Asset Category | Amount (KRW) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | ₩0.00 | 25.7% |
| Accounts Receivable | ₩228.83 Billion | 19.1% |
| Inventory | ₩100.24 Billion | 8.4% |
| Property, Plant & Equipment | ₩0.00 | 0.0% |
| Intangible Assets | ₩49.56 Billion | 4.1% |
| Goodwill | ₩1.65 Billion | 0.1% |
Asset Composition Trend (2016–2025)
This chart illustrates how Sk Biopharmaceuticals Co Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see 326030 stock market capitalisation.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Sk Biopharmaceuticals Co Ltd's current assets represent 57.0% of total assets in 2025, a decrease from 90.2% in 2016.
- Cash Position: Cash and equivalents constituted 25.7% of total assets in 2025, up from 19.9% in 2016.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 4.0% of total assets, an increase from 0.0% in 2016.
- Asset Diversification: The largest asset category is accounts receivable at 19.1% of total assets.
Sk Biopharmaceuticals Co Ltd Competitors by Total Assets
Key competitors of Sk Biopharmaceuticals Co Ltd based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
argenx NV ADR
NASDAQ:ARGX
|
USA | $8.68 Billion |
|
Ascendis Pharma AS
F:A71
|
Germany | €2.00 Billion |
|
Halozyme Therapeutics Inc
NASDAQ:HALO
|
USA | $2.22 Billion |
|
Chongqing Zhifei Bio Products
SHE:300122
|
China | CN¥29.09 Billion |
|
Camurus AB
ST:CAMX
|
Sweden | Skr4.74 Billion |
|
Zealand Pharma A/S
CO:ZEAL
|
Denmark | Dkr16.46 Billion |
|
Disc Medicine Inc.
NASDAQ:IRON
|
USA | $750.21 Million |
|
Bicara Therapeutics Inc. Common Stock
NASDAQ:BCAX
|
USA | $553.60 Million |
Sk Biopharmaceuticals Co Ltd - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 2.31 | 1.64 | 8.34 |
| Quick Ratio | 1.97 | 1.36 | 7.89 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | ₩388.03 Billion | ₩255.10 Billion | ₩486.62 Billion |
Sk Biopharmaceuticals Co Ltd - Advanced Valuation Insights
This section examines the relationship between Sk Biopharmaceuticals Co Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 9.57 |
| Latest Market Cap to Assets Ratio | 0.00 |
| Asset Growth Rate (YoY) | 15.6% |
| Total Assets | ₩1.20 Trillion |
| Market Capitalization | $4.67 Billion USD |
Valuation Analysis
Below Book Valuation: The market values Sk Biopharmaceuticals Co Ltd's assets below their book value (0.00x), which may indicate investor concerns about asset quality or future growth.
Rapid Asset Growth: Sk Biopharmaceuticals Co Ltd's assets grew by 15.6% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Sk Biopharmaceuticals Co Ltd (2016–2025)
The table below shows the annual total assets of Sk Biopharmaceuticals Co Ltd from 2016 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | ₩1.20 Trillion ≈ $812.08 Million |
+15.58% |
| 2024-12-31 | ₩1.04 Trillion ≈ $702.63 Million |
+43.37% |
| 2023-12-31 | ₩723.17 Billion ≈ $490.08 Million |
+8.87% |
| 2022-12-31 | ₩664.24 Billion ≈ $450.15 Million |
+3.20% |
| 2021-12-31 | ₩643.65 Billion ≈ $436.19 Million |
+28.67% |
| 2020-12-31 | ₩500.24 Billion ≈ $339.01 Million |
+259.70% |
| 2019-12-31 | ₩139.07 Billion ≈ $94.25 Million |
+45.57% |
| 2018-12-31 | ₩95.54 Billion ≈ $64.74 Million |
-2.88% |
| 2017-12-31 | ₩98.37 Billion ≈ $66.66 Million |
-49.27% |
| 2016-12-31 | ₩193.89 Billion ≈ $131.40 Million |
-- |
About Sk Biopharmaceuticals Co Ltd
SK Biopharmaceuticals Co., Ltd., a pharmaceutical company, engages in the research, development, and commercialization of drugs for the treatment of central nervous system disorders. The company offers Cenobamate, an anti-seizure medication for the treatment of epilepsy and Solriamfetol medication. It develops Carisbamate that is in Phase 3 trials to treat lennox-gastaut syndrome; Relenopride, wh… Read more